Research Topics
Genomes and Genes | Nancy E DavidsonSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Adjuvant endocrine therapy for premenopausal women with early breast cancerTing Bao
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
Breast Cancer Res 9:115. 2007....
What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?Tatiana M Prowell
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 409, Baltimore, Maryland 21231 1000, USA
Oncologist 9:507-17. 2004....- Ongoing US cooperative group trials using taxanes in the adjuvant settingNancy E Davidson
Johns Hopkins Oncology Center, Baltimore, MD 21231 1000, USA
Clin Breast Cancer 3:S53-8. 2002..Ongoing trials will help to further define the role of taxanes in the adjuvant setting for patients with operable breast cancer... - The maturation of medical oncologyNancy E Davidson
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Lancet Oncol 8:457-8. 2007 - Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)Nancy E Davidson
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 409, Baltimore, MD 21231, USA
J Clin Oncol 23:5973-82. 2005..Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established... - Spermine oxidase SMO(PAOh1), Not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell linesAllison Pledgie
Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, Maryland 21231, USA
J Biol Chem 280:39843-51. 2005..These data suggested that SSAT and SMO(PAOh1) activities are the major mediators of the cellular response of breast tumor cells to BENSpm and that PAO plays little or no role in this response... - Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cellsYi Huang
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD and SLIL Biomedical Corp, Madison, WI, USA
Mol Cancer Res 2:81-8. 2004.... - Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cellsYi Huang
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
J Biol Chem 281:19055-63. 2006..Taken together, these results suggest a novel antiestrogenic mechanism for specific polyamine analogues in human breast cancer cells... - Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cellsQun Zhou
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB Room 144, Baltimore, MD 21231, USA
Mol Cancer Res 6:873-83. 2008..Our studies suggest a new role for HDAC1 and identify a novel mechanism of action for the HDAC inhibitors as down-regulators of DNMT1... 
Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cellsMadhavi Billam
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21231, USA
Breast Cancer Res Treat 120:581-92. 2010..These findings suggest that zebularine is an effective DNMT inhibitor and demethylating agent in human breast cancer cell lines and potentiates the effects of other epigenetic therapeutics like decitabine and vorinostat...- Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profilesAbena S Agyeman
Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Breast Cancer Res Treat 132:175-87. 2012..Collectively, these studies served to identify potential biomarkers that can be used in clinical trials to investigate the initial pharmacodynamic action of SFN in the breast... - Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cellsJudith C Keen
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Cancer Biol Ther 3:1304-12. 2004..These gene products may be novel targets to be further explored in the development of new therapeutics for ER negative breast cancer... - Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cellsQun Zhou
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRBI Room 144, Baltimore, MD 21231, USA
Breast Cancer Res Treat 117:443-51. 2009..Thus, SAHA may not only reactivate silenced ER, but also simultaneously deplete EGFR expression. These data suggest that inhibition of HDAC is a promising epigenetic therapy for ER-negative human breast cancer... - Epigenetic regulation as a new target for breast cancer therapyVered Stearns
Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
Cancer Invest 25:659-65. 2007 - Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancerMichael A Jacobs
The Russell H Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Acad Radiol 17:1477-85. 2010..The aim of this prospective study was to investigate using multiparametric and multinuclear magnetic resonance imaging during preoperative systemic therapy for locally advanced breast cancer... - Inhibition of estrogen signaling activates the NRF2 pathway in breast cancerYuan Yao
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Breast Cancer Res Treat 124:585-91. 2010..Moreover, shikonin reverses the inhibitory effects of estrogen on this pathway and may contribute to breast cancer prevention... - PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?Ben Ho Park
Breast Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA
Cancer Cell 12:297-9. 2007..This study extends important work of others and forms the rationale for future investigations combining inhibitors of the PI3 kinase pathway in conjunction with trastuzumab therapy... - Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cellsDipali Sharma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 409, Baltimore, MD 21231, USA
Mol Endocrinol 19:1740-51. 2005..These findings will aid in the application of agents targeting epigenetic changes in the treatment of breast cancer... - A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancerMichaela J Higgins
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRBI, Room 144, Baltimore, MD 21231, USA
Breast Cancer Res Treat 131:915-24. 2012..Simvastatin appears to modulate estrone sulfate concentrations and its potential chemopreventive activity in breast cancer warrants further investigation... - Sulforaphane induces cell type-specific apoptosis in human breast cancer cell linesAllison Pledgie Tracy
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1550 Orleans Street, Baltimore, MD 21231, USA
Mol Cancer Ther 6:1013-21. 2007..These results support testing sulforaphane in vivo and warrant future studies examining the clinical potential of sulforaphane in human breast cancer... - Adjuvant hormonal therapy for premenopausal women with breast cancerRegina J Brown
Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000, USA
Semin Oncol 33:657-63. 2006..Other research focuses on identification of improved markers for endocrine response or resistance and on the special side effects of endocrine therapy in young women... - Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrenceHetty E Carraway
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD 21231, USA
Breast Cancer Res Treat 114:315-25. 2009..This study evaluates the methylation frequency and pattern in HNSN to determine if detection of hypermethylation of one or more genes is associated with an increased recurrence risk in node negative breast cancer... - Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cellsQingsong Zhu
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Amino Acids 42:887-98. 2012..These data indicate that the pharmacologic inhibition of LSD1 can effectively alter gene expression and that this therapeutic strategy has potential... - Role of p53/p21(Waf1/Cip1) in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cellsYi Huang
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
Cancer Biol Ther 4:1006-13. 2005..Understanding the mechanism of p53-mediated cellular responses to polyamine analogue may help to improve the therapeutic efficacy of polyamine analogues in human breast cancer... - Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationLeisha A Emens
Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Clin Oncol 27:5911-8. 2009..We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer... - Inhibition of SIRT1 deacetylase suppresses estrogen receptor signalingYuan Yao
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Carcinogenesis 31:382-7. 2010..These results suggest that inhibition of SIRT1 deacetylase activity by either pharmacological inhibitors or genetic depletion impairs ERalpha-mediated signaling pathways... - Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylationQun Zhou
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB Room 409, Baltimore, Maryland 21231, USA
Cancer Biol Ther 6:64-9. 2007..Our findings suggest that HDAC inhibitors could restore expression of the silenced ER gene by reorganizing the heterochromatin-associated proteins without alteration in promoter DNA hypermethylation... - Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozoleTatiana M Prowell
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Cancer Prev Res (Phila) 4:1993-2001. 2011.... - Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stabilityJudith C Keen
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
J Biol Chem 280:29519-24. 2005..These data suggest a novel pathway controlling ER expression resulting from the activation of PP2A, potentially providing a novel therapeutic target... - A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancerAntonio C Wolff
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
Clin Cancer Res 9:5922-8. 2003..This study evaluated the activity of the first-generation analog DENSpm in women with metastatic breast cancer... - Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cellsQun Zhou
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, USA
Proteomics 10:1029-39. 2010..Knowledge of the full repertoire of acetylated proteins will provide a foundation for further defining the functions of HDACs in cancer cells... - The silent estrogen receptor--can we make it speak?Madhavi Billam
The Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University, 1650 Orleans St, Baltimore, MD 21231, USA
Cancer Biol Ther 8:485-96. 2009..Here we will focus especially on silencing the expression of ERα as one such endocrine-resistance mechanism and how it might be exploited clinically... - A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidineJudith Clancy Keen
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000, USA
Breast Cancer Res Treat 81:177-86. 2003..These data suggest that Scriptaid or related HDAC inhibitors are candidates for further study in breast cancer... - Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastasesJulie M Wu
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
Clin Cancer Res 14:1938-46. 2008..A comprehensive comparison of biomarker expression between patients' primary breast carcinoma (PBC) and their metastatic breast carcinomas (MBC) has not been done... - New findings about endocrine therapy for breast cancerNancy E Davidson
Johns Hopkins University, Schools of Medicine and Public Health, Baltimore, MD, USA
Breast 12:368-72. 2003..Ongoing research is focused on choice of endocrine approach, duration and sequencing of endocrine treatment, identification of better predictive markers for hormone response, and assessment of long-term risks and benefits... - Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198Antonio C Wolff
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
Breast Cancer Res Treat 121:111-20. 2010..In conclusion, concurrent administration of trastuzumab with PLD-docetaxel was not associated with higher risk of cardiac toxicity compared with PLD-docetaxel alone, but led to excessive hand-foot syndrome... - Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancerRichard C Zellars
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins, 401 N Broadway, Suite 1440, Baltimore, MD 21231, USA
J Clin Oncol 27:2816-22. 2009..We hypothesized that anthracycline-based chemotherapy and concurrent partial breast irradiation (PBI) is safe and conducted a single-arm feasibility trial testing this hypothesis with dose-dense doxorubicin and cyclophosphamide (ddAC)... - The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathwayKideok Jin
Breast Cancer Program, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
Proc Natl Acad Sci U S A 109:2736-41. 2012..These studies suggest that HOXB7 acts as a key regulator, orchestrating a major group of target molecules in the oncogenic hierarchy. Functional antagonism of HOXB7 could circumvent tamoxifen resistance... - Anticancer activities of novel chalcone and bis-chalcone derivativesAneta Modzelewska
Division of Chemical Therapeutics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Bioorg Med Chem 14:3491-5. 2006..Furthermore, bis-chalcone 8 exhibited a more potent inhibition of colon cancer cells expressing wild-type p53 than of an isogenic cell line that was p53-null... - A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancerLeisha A Emens
Johns Hopkins Oncology Center, Baltimore, MD, USA
Breast Cancer Res Treat 76:145-56. 2002..Our aims were to determine the maximum tolerated dose (MTD) of 5-FU in the dose-dense regimen and to determine the impact of dose-dense chemotherapy on HDC/PBSCT... - Adjuvant hormonal therapy for premenopausal women with breast cancerLeisha A Emens
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-1000, USA
Clin Cancer Res 9:486S-94S. 2003.... - Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancerRoisin M Connolly
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 189, Baltimore, MD 21231 1000, USA
Breast Cancer Res Treat 127:153-62. 2011..However, these unexpected pharmacokinetic findings support further investigation of mechanisms underlying docetaxel elimination pathways... - What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?Michaela J Higgins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Curr Oncol Rep 11:45-50. 2009..This review focuses on new data on how to incorporate OS/OA into the rational treatment of this challenging patient population... - Induction of spermidine/spermine N1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N1, N11-diethylnorspermineEdward Gabrielson
Department of Pathology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231-1000, USA
Cancer Chemother Pharmacol 54:122-6. 2004..A high proportion of breast cancers induced SSAT in response to DENSpm, supporting the continued consideration of this class of agents for treatment of breast cancer... - Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphoniumIgal Madar
Russell H Morgan Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
J Nucl Med 50:774-80. 2009..Here, we have characterized the ability of the novel PET voltage sensor (18)F-fluorobenzyl triphenyl phosphonium ((18)F-FBnTP) to quantify the time-dependent apoptotic action of the taxanes paclitaxel and docetaxel in vitro and in vivo... - Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancerAditya Bardia
Breast Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building 1, Room 144, 1650 Orleans Street, Baltimore, MD 21231, USA
Breast Cancer Res Treat 131:907-14. 2012..Physicians should weigh competing risks and offer early screening and cardiac prevention strategies for women at a greater risk for CVD... - Aromatase inhibitors as adjuvant therapy in breast cancerKala Visvanathan
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
Oncology (Williston Park) 17:335-42, 347; discussion 347-50, 354. 2003..Ongoing trials are assessing the potential role of aromatase inhibitors in the adjuvant, neoadjuvant, and preventive settings... - Preoperative therapy in breast cancer: lessons from the treatment of locally advanced diseaseAntonio C Wolff
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
Oncologist 7:239-45. 2002..PST is increasingly being used in otherwise operable stage I and II patients aiming at greater rates of breast conservation and earlier efficacy assessment. This article reviews many of these issues and ongoing research questions... - Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluidMary Jo Fackler
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore Maryland, USA
Clin Cancer Res 12:3306-10. 2006..This study provides proof of principle by showing the advantages of using methylation analyses to query cytologic specimens and indicates its potential use in diagnosis and in stratifying risk... - Case records of the Massachusetts General Hospital. Case 35-2005. A 56-year-old woman with breast cancer and isolated tumor cells in a sentinel lymph nodeNancy E Davidson
Johns Hopkins University School of Medicine, Baltimore, USA
N Engl J Med 353:2177-85. 2005 - Estrogen receptor status, cell cycling and paclitaxel: looking for a "hormone"-ious explanationBen Ho Park
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, Maryland 21231, USA
Cancer Biol Ther 3:468-9. 2004 - Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193Antonio C Wolff
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
Clin Breast Cancer 6:334-9. 2005..The purpose of this multicenter phase II trial was to evaluate the clinical activity of topotecan as first-line chemotherapy in patients with metastatic breast cancer and previous exposure to adjuvant doxorubicin... - The follow-up of breast cancerLeisha A Emens
Department of Oncology, The Johns Hopkins University, Baltimore, MD, USA
Semin Oncol 30:338-48. 2003..Finally, we present an evidence-based approach to breast cancer surveillance after therapy that is consistent with several clinical practice guidelines, maximizing outcome and minimizing cost... - Martin D. Abeloff, MDNancy E Davidson
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
J Clin Oncol 26:1573-4. 2008 - A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cellsYi Huang
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
Clin Cancer Res 9:2769-77. 2003.... - Molecular mechanisms of polyamine analogs in cancer cellsYi Huang
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Anticancer Drugs 16:229-41. 2005..The development and use of these analogs have provided valuable information for understanding the molecular mechanisms of targeting the polyamine pathway as a means of cancer therapy... - Aromatase inhibitors for breast cancerSusanne Briest
Department of Gynecology and Obstetrics, University of Leipzig, Leipzig, Germany
Rev Endocr Metab Disord 8:215-28. 2007..Here the use of aromatase inhibitors for treatment of postmenopausal endocrine-responsive breast cancer in the metastatic, adjuvant, and preoperative settings is reviewed... - Exercise manages fatigue during breast cancer treatment: a randomized controlled trialVictoria Mock
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, USA
Psychooncology 14:464-77. 2005..Adherence to a home-based moderate-intensity walking exercise program may effectively mitigate the high levels of fatigue prevalent during cancer treatment... - Gene expression profiling of breast cancerTing Bao
The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, 1650 Orleans Street, Baltimore, Maryland 21231, USA
Adv Surg 42:249-60. 2008..It is expected that availability of these types of analyses will only increase in the future. It will be imperative that such assays be well validated and have implications for how to modify care for the individual patient... - Estrogen carcinogenesis in breast cancerJames D Yager
Bloomberg School of Public Health, Department of Environmental Health Sciences, Johns Hopkins University, Baltimore, MD 21205, USA
N Engl J Med 354:270-82. 2006 - The importance of cytologic intrarater and interrater reproducibility: the case of ductal lavageKala Visvanathan
Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA
Cancer Epidemiol Biomarkers Prev 15:2553-6. 2006..27 +/- 0.09. Fair to moderate intrarater and interrater agreement of DL cytology was observed. Low intrarater and interrater cytologic consistency may compromise the interpretation of clinical studies of DL... - Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancerAgoston T Agoston
Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, School of Medicine, Baltimore, Maryland 21231 1000, USA
J Biol Chem 280:18302-10. 2005..The regulation of DNMT1 destruction via this domain may be dysfunctional in cancer cells leading to subsequent cytosine hypermethylation in the genome... - Silencing estrogen receptor alpha in breast cancer cellsQun Zhou
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
Cancer Biol Ther 5:848-9. 2006 - Of Snail, mice, and womenNancy E Davidson
Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
Cancer Cell 8:173-4. 2005..The identification of a molecular pathway involved in mammary tumor recurrence in a mouse model offers both opportunity and challenge to confirm, extend, and exploit these findings in the clinic... - Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breastBrian S Cornblatt
Department of Environmental Health Sciences, Johns Hopkins University Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA
Carcinogenesis 28:1485-90. 2007..These findings provide a strong rationale for evaluating the protective effects of a broccoli sprout preparation in clinical trials of women at risk for breast cancer... - Tracking 35 years of progress against breast cancerNancy E Davidson
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, USA
Oncology (Williston Park) 22:593-5. 2008 - Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometryJinong Li
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
Clin Chem 51:2229-35. 2005..C3a(desArg) appears to lack specificity among patients with benign diseases, limiting its utility as a stand-alone tumor marker, but it may still be useful in a multimarker panel for early detection of breast cancer... - Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applicationsMichael A Jacobs
The Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Technol Cancer Res Treat 3:543-50. 2004..A combination of MR, MRSI, and 23Na sodium MR parameters may be examined in a single MR imaging examination, potentially resulting in improved specificity for radiologic evaluation of malignancy... - Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agentsSrinivas K Kumar
Division of Experimental Therapeutics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
J Med Chem 46:2813-5. 2003..The results show the boronic-chalcones are more toxic to breast cancer cells compared to normal breast cells than other known chalcones... - The biology of breast carcinomaJudith Clancy Keen
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
Cancer 97:825-33. 2003..Studies of the biology of these and other genes that contribute to the development and progression of breast carcinoma have had and will continue to have great impact on all aspects of disease management... - Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196Joseph A Sparano
Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10461, USA
J Clin Oncol 22:4683-90. 2004..To determine whether a matrix metalloproteinase inhibitor improves progression-free survival (PFS) in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy... - Trastuzumab in breast cancerLeisha A Emens
Breast Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine Baltimore, Maryland 21231-1000, USA
Oncology (Williston Park) 18:1117-28; discussion 1131-2, 1137-8. 2004..Here we review the clinical development of this novel agent, emphasizing the potential for therapeutic synergy when trastuzumab is combined with both standard chemotherapy and innovative molecularly targeted and biologic agents... - Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant TrialEdith A Perez
North Central Cancer Treatment Group, Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
J Clin Oncol 22:3700-4. 2004.... - Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratorySunil S Badve
Eastern Cooperative Oncology Group, Boston, MA, USA
J Clin Oncol 26:2473-81. 2008.... - Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831Patrick C Roche
Mayo Clinic and Mayo Foundation, Rochester, MN, USA
J Natl Cancer Inst 94:855-7. 2002..The concordance for central HercepTest and central FISH assays was 92%. The poor concordance (74%) between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831... - Déjà vu for breast cancer two?Vered Stearns
J Natl Cancer Inst 96:497-9. 2004 - Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell linesLan Yan
Sidney Kimmel Comprehensive Cancer at Johns Hopkins University Medical School, Baltimore, Maryland USA
Cancer Biol Ther 2:552-6. 2003..Our results suggest that specific inhibition of DNMT1 expression alone is sufficient to re-express ERa in human breast cancer cell lines... - A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss
Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
N Engl J Med 349:1793-802. 2003..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy... - Breast cancer consensus meetings: vive la difference?Nancy E Davidson
J Clin Oncol 20:1719-20. 2002 - Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and LeukemiaMarc L Citron
ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
J Clin Oncol 21:1431-9. 2003.... - Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic featuresLori J Goldstein
Eastern Cooperative Oncology Group, Boston, MA, USA
J Clin Oncol 26:4063-71. 2008..Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than clinicopathologic features... - Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197Lori J Goldstein
Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
J Clin Oncol 26:4092-9. 2008..The purpose of this trial was to determine whether adjuvant AT improved disease-free survival compared with AC in operable breast cancer... - Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexesDipali Sharma
Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Cancer Res 66:6370-8. 2006..The mechanistic insight provided by this study might help in designing therapeutic strategies directed toward epigenetic mechanisms in the prevention or treatment of breast cancer... - HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trialEdith A Perez
Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
J Clin Oncol 24:3032-8. 2006..To evaluate concordance between local and central laboratory HER2 testing results in patients from the North Central Cancer Treatment Group (NCCTG) N9831 adjuvant trial of trastuzumab... - American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant settingJames L Khatcheressian
Virginia Commonwealth University/Massey Cancer Center, Richmond, VA, USA
J Clin Oncol 24:5091-7. 2006..CONCLUSION: Careful history taking, physical examination, and regular mammography are recommended for appropriate detection of breast cancer recurrence... - Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancerAntonio C Wolff
J Clin Oncol 24:4949-51. 2006 - A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology GroupRobert W Carlson
Stanford University, Stanford, California 94305 5826, USA
Cancer Invest 24:677-81. 2006..To assess the activity and toxicity of valspodar (PSC-833) in combination with paclitaxel in women with anthracycline refractory, metastatic breast cancer... - Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle
Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
Breast Cancer Res Treat 99:295-300. 2006..CONCLUSION: These analyses suggest that, at least out to about 48 months, longer duration of letrozole treatment is associated with greater benefit in the extended adjuvant therapy setting... - A "bone" fide predictor of metastasis? Predicting breast cancer metastasis to boneScott L Kominsky
J Clin Oncol 24:2227-9. 2006 - Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim supportAntonio C Wolff
J Clin Oncol 24:2392-4; author reply 2394-5. 2006 - Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss
Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
J Clin Oncol 25:2006-11. 2007..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status... - Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell deathMeihua Sui
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
Cancer Res 67:5337-44. 2007..The results obtained from this study provide useful information for understanding ER-mediated resistance to paclitaxel and possibly other antineoplastic agents... - Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancerNancy E Davidson
J Natl Cancer Inst 97:159-61. 2005 - Weekly paclitaxel in the adjuvant treatment of breast cancerJoseph A Sparano
Eastern Cooperative Oncology Group, Philadelphia, USA
N Engl J Med 358:1663-71. 2008..We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer... - Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerKathy Miller
Indiana University Cancer Center, Indianapolis, USA
N Engl J Med 357:2666-76. 2007.... - Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss
Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
J Natl Cancer Inst 97:1262-71. 2005..This report presents updated findings from the trial... - Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss
Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
J Clin Oncol 26:1948-55. 2008..When the trial was unblinded, patients who received placebo (PLAC) were offered LET... - Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialEdith A Perez
Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
J Clin Oncol 26:1231-8. 2008..To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial... - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
N Engl J Med 353:1673-84. 2005..CONCLUSIONS: Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.).. - P7 antigen expression in human breast cancerXiaowei Yang
Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California 90033, USA
Clin Cancer Res 9:201-6. 2003..The markedly increased expression in patients with locally advanced disease after neoadjuvant therapy suggests a role for p7 in treatment outcome... - Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196Stanley Zucker
Veterans Affairs Medical Center, Northport, NY State University Hospital of New York, Stony Brook, USA
Clin Breast Cancer 6:525-9. 2006..CONCLUSION: We conclude that measurement of plasma MMP-7 or MMP-9 levels, as performed in our trial, was not a useful prognostic or predictive factor in patients with MBC or in patients treated with an MMPI...
Research Grants
- DNA METHYLATION AS A DETERMINANT OF BREAST CANCERNancy Davidson; Fiscal Year: 2002..Taken together these studies should provide new insights into the biology of hormone resistance and possible novel therapeutic targets. ..
- SPORE IN BREAST CANCERNancy Davidson; Fiscal Year: 2007....